Open an account

Immix Biopharma

IMMX · NASDAQ

$8.91+$0.69 (+8.39%)TodayMarket closed ·
Prev close $8.22

About IMMX

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 21 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Employees
21
Headquarters
Los Angeles, California
Listed
Dec 16, 2021
Sector
Health Care
Industry
Biotechnology
Website
immixbio.com

IMMX key statistics

Market cap
738.67M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.68M
Volume
1.23M
Open price
$8.26
High today
$9.03
Low today
$8.24
52 Week high
$15.10
52 Week low
$2.71

Immix Biopharma (IMMX) at a glance

Immix Biopharma (IMMX) last traded at $8.91, with a market cap of 738.67M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $8.24 and $9.03. The current price is 8.2% above the day's low and 1.3% below its high.

Volume so far is 1.23M shares, below the average of 1.68M shares a day.

Over the past year Immix Biopharma has ranged from $2.71 to $15.10, and now sits 50% of the way up that range.

Immix Biopharma met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.18 per share against an estimate of -$0.1792.

The average analyst price target is $25.04, 181.0% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 8 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $25.04
Low
$17.57
Now
$8.91
High
$31.50

IMMX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 29.5% on average.

  1. Q3 FY24: reported -$0.24 per share against an estimate of -$0.1632
  2. Q4 FY24: reported -$0.16 per share against an estimate of -$0.255
  3. Q1 FY25: reported -$0.15 per share against an estimate of -$0.2346
  4. Q2 FY25: reported -$0.22 per share against an estimate of -$0.1632
  5. Q3 FY25: reported -$0.24 per share against an estimate of -$0.1938
  6. Q4 FY25: reported -$0.28 per share against an estimate of -$0.1591
  7. Q1 FY26: reported -$0.18 per share against an estimate of -$0.2124
  8. Q2 FY26: reported -$0.18 per share against an estimate of -$0.1792

IMMX news

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

  • Press releaseBusiness Wire

    IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

  • Press releaseGlobe Newswire

    IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.

  • Press releaseGlobe Newswire

    IMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & Leviton; Investors Should Contact the Firm

  • Watching Immix Biopharma; Shares Trading Lower, Traders Circulate STAT News Article Titled 'A Most-Wanted Fugitive Appears To Have Been Secretly Working As A Biotech Executive'

Similar companies

Companies in the same industry as Immix Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.